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The regulated secretory pathway provides critical control of peptide, growth factor, and
hormone release from neuroendocrine and endocrine cells, and neurons, maintaining
physiological homeostasis. Propeptides and prohormones are packaged into dense core
granules (DCGs), where they frequently undergo tissue-specific processing as the DCG
matures. Proteins of the granin family are DCG components, and although their function
is not fully understood, data suggest they are involved in DCG formation and regulated
protein/peptide secretion, in addition to their role as precursors of bioactive peptides.
Association of gene variation, including single nucleotide polymorphisms (SNPs), with neu-
ropsychiatric, endocrine, and metabolic diseases, has implicated specific secreted proteins
and peptides in disease pathogenesis. For example, a SNP at position 196 (G/A) of the
human brain-derived neurotrophic factor gene dysregulates protein processing and secre-
tion and leads to cognitive impairment.This suggests more generally that variants identified
in genes encoding secreted growth factors, peptides, hormones, and proteins involved in
DCG biogenesis, protein processing, and the secretory apparatus, could provide insight
into the process of regulated secretion as well as disorders that result when it is impaired.
Keywords: single nucleotide polymorphism (SNP), dense core granule (DCG), insulin, brain-derived neurotrophic
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GENERAL OVERVIEW OF REGULATED SECRETION
Neuronal and endocrine peptides, growth factors, and hormones
maintain physiological homeostasis. Their release is therefore
tightly controlled by regulated secretion (1). Messenger RNAs
(mRNAs) are translated and secreted proteins enter the cis-
ternae of the rough endoplasmic reticulum (RER), are trans-
ported to the trans-Golgi network (TGN), are targeted into
immature dense core granules (DCGs), and are retained in
mature DCGs (also called large dense core vesicles or LDCVs),
in endocrine and neuronal cells. Proteins including members
of the granin family, such as chromogranin A (CgA), chromo-
granin B (CgB), secretogranin II (SgII), and secretogranin III
(SgIII), the exopeptidase carboxypeptidase E (CPE), and prohor-
mone convertases 1/3 and 2 (PC1/3 and PC2), are also sorted
into DCGs, which in addition, increase the diversity of bio-
logically active peptides through processing of granin precursor
proteins (2).
Although the sorting of proteins into DCGs is not fully under-
stood, interaction of DCG cargo proteins with TGN lipid raft-
anchoring or membrane-spanning proteins (SgIII, CPE, sortilin)
plays an essential role in docking and concentrating of DCG com-
ponents and is critical for the correct sorting of cargo proteins and
for vesicle biogenesis (3, 4). DCG sorting domains have been iden-
tified in prohormones, propeptides, and granins, and although
not highly conserved, these polypeptide motifs are required for
regulated secretion. After budding from the TGN, immature DCGs
undergo acidification, mediated by the DCG membrane-spanning
proton pump, leading to activation of resident prohormone con-
vertases and carboxypeptidases. All granin members and most
other propeptides,prohormones,and prohormone convertases are
known to undergo proteolytic processing during granule matura-
tion, which is essential for enzymatic activation and the generation
of biologically active peptides.
Granin family members, including CgA, CgB, SgII, and SgIII,
are the most abundant DCG components, with CgA, for exam-
ple, constituting almost half of the soluble protein content of the
adrenal chromaffin cell secretory granule (5). The importance
of granin proteins in vesicle biogenesis has been demonstrated
by overexpression of CgA or CgB in cells that lack a classical
regulated secretory pathway, such as fibroblasts, which results
in the production of granule-like structures and the regulated
release of vesicle contents (6, 7). Moreover, gene silencing studies
demonstrate reciprocal effects on DCG biogenesis, with decreased
DCG number reported in PC12 cells that contain reduced lev-
els of CgA or SgII, and in the adrenal medulla of CgA knockout
mouse (8–10). Other CgA and CgB knockout mouse models,
although showing no change in DCG number in adrenal medulla
and other endocrine tissues, were found to have increased levels
of other granin proteins, which is likely due to compensatory
mechanisms (11, 12).
www.frontiersin.org August 2013 | Volume 4 | Article 96 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lin and Salton SNPs that impact regulated secretion
MECHANISMS BY WHICH GENETIC VARIANTS CAN IMPACT
SECRETED PROTEINS
Single nucleotide polymorphisms (SNPs) are the most common
genetic variations in genomic DNA, occurring 1/1200 bp on aver-
age (13). Individual SNPs submitted to the Single Nucleotide Poly-
morphism Database (dbSNP), a service provided by the National
Center for Biotechnology Information (NCBI), are assigned a
unique reference SNP ID number (rs#) to map the SNP to other
external databases. Many SNPs are silent variations and their
occurrence does not affect gene expression or protein function.
However, a single nucleotide change has the potential to modulate
protein level or function if the SNP is located: (1) in the promoter
region, which may alter transcriptional activity, (2) in intronic
regions, which may interfere with splicing efficiency if the SNP is
found at exon-intron boundaries in splice donor sites, regulatory
sequences, or splice acceptor sites, (3) in the 3′ untranslated region
(3′UTR), which may affect the expression levels of either mRNA
or protein due to altered cis-elements including mRNA destabi-
lization sequences, AU-rich elements, and translational repressor
binding sites, including miRNA targeting sites, and (4) in the
protein coding region, which can cause missense or nonsense
mutations. Nonsense mutations can result in premature termi-
nation of translation and the production of truncated proteins,
while missense mutations can lead to loss-of-function or gain-
of-function. With respect to proteins in the regulated secretory
pathway, missense SNPs could impact enzymatic catalytic activity,
alter peptide affinity for receptors, impair protein sorting when
found in targeting motif(s) of secretory proteins, or block peptide
processing when located in the cleavage sites of prohormones or
propeptides (Figure 1).
REPORTED SNPs IN GENES ENCODING SECRETED PROTEINS
THAT ARE ASSOCIATED WITH NEUROPSYCHIATRIC OR
ENDOCRINE/METABOLIC DISEASE
Neurotrophic growth factors, hormones, peptide precursors, pro-
hormone convertases, granins, and other DCG proteins are
secreted through the regulated or constitutive secretory pathways.
Even relatively subtle changes in protein processing, levels, or reg-
ulated secretion, due to specific SNPs that impact a variety of
proteins in the secretory pathway, have been reported to be associ-
ated with neuropsychiatric or metabolic disease, and these studies
are reviewed below.
NEUROTROPHINS
Brain-derived neurotrophic factor
Brain-derived neurotrophic factor (BDNF) is well known for its
role in regulating neuroplasticity and neurogenesis in the brain. A
functional variant in the propeptide domain of BDNF, SNP rs6265
(G- to A-allele, Val66Met), was found to affect the secretion of
BDNF (14). Previous biochemical studies have shown that BDNF
(Met66, encoded by minor A-allele) fails to bind to sortilin through
its pro-domain region, and this lowers its activity-dependent
secretion due to failed DCG sorting and localization (14, 15).
BDNF (Met66) is associated with reduced brain volume, impaired
episodic memory (16), and high trait anxiety (17). Two other
SNPs located at the protease cleavage site of the proBDNF pro-
tein, SNPs rs1048220 (G- to T-allele, Arg125Met) and rs1048221
(G- to T-allele, Arg127Leu), partially impair proBDNF cleavage
but not DCG sorting and secretion (18). The minor alleles of SNP
rs1048220 (T-allele) and SNP rs1048218 (T-allele) have also been
associated with familial and sporadic Alzheimer’s disease (19).
Nerve growth factor
Mature nerve growth factor (NGF) binds to tropomyosin-related
kinase A (TrkA) receptor tyrosine kinase and activates signal-
ing pathways that regulate neuronal differentiation and survival.
Unprocessed proNGF, however, has higher binding affinity for the
p75NTR neurotrophin receptor, and can stimulate either cell sur-
vival or programed cell death (20). SNP rs6330 (C- to T-allele,
Ala35Val) was previously identified in the pro-domain region of
NGF, which has the potential to alter the efficiency of proNGF sort-
ing or processing. The nucleotide variant of SNP rs6330 was found
to be associated with increased anxiety in women (C-allele) (21),
was over-transmitted in Attention Deficit Hyperactivity Disorder
(ADHD)-affected children (C-allele) (22), and was associated with
Alzheimer’s disease onset (both C- and minor T-alleles) (19, 23).
NEUROPEPTIDES
Proopiomelanocortin
Expression of proopiomelanocortin (POMC), the precursor of
several processed neuropeptides [α-MSH, adrenocorticotrophic
hormone (ACTH), β-MSH, and β-endorphin], is regulated by
the adipocyte-derived hormone leptin, which signals by bind-
ing receptors on neurons in the hypothalamic arcuate nucleus.
The POMC-derived peptide α-MSH activates the melanocortin
4-receptor (MC4R) and suppresses food intake. Lack of POMC
in humans and mouse models leads to the development of severe
obesity, ACTH deficiency, and hypopigmentation (24, 25). A mis-
sense amino acid substitution by SNP rs28932472 (G- to C-allele,
Arg236Gly) in the POMC gene was reported to disrupt the dibasic
processing site between β-MSH and β-endorphin. The minor C-
allele that encodes POMC (Gly236) results in an aberrant fusion
peptide of β-MSH and β-endorphin, which still binds to the
MC4R but antagonizes its activation. As a consequence, the Gly236
variation is associated with early onset obesity in several ethnic
groups (26).
Agouti-related peptide
Expressed in the arcuate nucleus of the hypothalamus, agouti-
related peptide (AgRP) is an endogenous antagonist of the MC4R
that increases feeding behavior. The amino acid substitution of
Ala67 to Thr67 caused by SNP rs5030980 (G- to A-allele) in the
AgRP gene is associated with Anorexia Nervosa and leanness (27).
In healthy subjects, homozygosity for the Thr67 allele is associated
with low body fat mass and low lean body mass, while the Ala67
allele is associated with late-onset obesity. Although the Thr67
variation results in no detectable change in binding to the MC4R
or sorting efficiency into and secretion from DCGs, the polar-
ity of the amino acid substitution may cause a conformational
change in AgRP, affecting other peptide functions that need further
characterization (28).
Neuropeptide Y
Neuropeptide Y (NPY) is a potent orexigenic peptide that is
also expressed in the hypothalamus. It regulates energy balance
Frontiers in Endocrinology | Neuroendocrine Science August 2013 | Volume 4 | Article 96 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lin and Salton SNPs that impact regulated secretion
FIGURE 1 | Regulated secretory pathway of a model neuroendocrine cell.
Single nucleotide polymorphisms (SNPs) can affect granule biogenesis and
release through these mechanisms: (1) SNPs in the promoter or 3′UTR of
granule-associated genes modulate gene expression levels, resulting in
altered granule biogenesis, (2) SNPs in the pro-domain of peptides or
hormones block their processing and/or sorting into the regulated pathway, (3)
SNPs in convertase/peptidase catalytic or regulatory domains reduce
enzymatic activity and lead to aberrant propeptide processing, (4) SNPs in the
signal peptide and/or sorting domain(s) disrupt regulated secretion, and (5)
SNPs that change the processing or sequence of neuropeptides modulate
membrane receptor binding affinity. TrkB, tropomyosin-related kinase B
receptor; INSR, insulin receptor.
through effects on energy intake, expenditure, and partition-
ing. A non-synonymous SNP rs16139 that leads to an amino
acid change (T- to C-allele, Leu7Pro) in the signal peptide
domain of preproNPY has been reported to cause a tertiary struc-
tural change in its sorting domain, and this Pro7 substitution
alters intracellular proNPY packaging, processing, and secretion
(29–31). NPY (Pro7) is associated with elevated food intake,
altered free fatty acid (FFA) metabolism and high serum cho-
lesterol and LDL cholesterol levels, but doesn’t affect insulin
sensitivity, insulin secretion, or glucose metabolism (30, 32,
33). Lower plasma NPY and norepinephrine concentrations,
and lower insulin but higher glucose concentrations in plasma,
were also reported in the population with the Pro7 substitu-
tion (34).
HORMONES
Insulin
A nucleotide variation in the proinsulin gene is located at the C-
peptide-A-chain junction (C65, causes Arg to His), and the His65
substitution prevents processing of the dibasic cleavage site, result-
ing in hyperproinsulinemia that is caused by the accumulation of a
circulating, biologically defective form of the proinsulin interme-
diate peptide, which fails to be metabolized via receptor-mediated
endocytosis (35). The other identified proinsulin nucleotide vari-
ation results in an amino acid substitution of B10 (His to Asp),
resulting in aberrant proinsulin sorting into the constitutive secre-
tory pathway and a subsequent failure in peptide processing,
which is also associated with hyperproinsulinemia in affected
individuals (36, 37).
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GRANINS
Proteins of the granin family, including the chromogranins and
secretogranins, have been demonstrated to play an important role
in DCG biogenesis, in neural, neuroendocrine, and endocrine cells
(2). It is not too surprising, then, that a number of SNPs which
alter granin expression levels have been associated with metabolic
diseases or neurological disorders, because physiological home-
ostasis is tightly regulated by neuropeptides, growth factors, and
hormones, all of which are processed and stored in DCGs.
Chromogranin A (CHGA)
The combination of SNPs that are inherited together is called a
haplotype, which can be used for studying genetic linkage of dis-
eases. Two haplotype polymorphism carriers, haplotype (A-T-C)
of SNPs rs9658634–rs9658635–rs7159323 in the CHGA promoter
region, and haplotype (T-C) of SNPs rs7610–rs875395 in the
CHGA 3′UTR and downstream regions, are linked to hyperten-
sive renal disease (38). SNP rs9658634 in the CHGA promoter
was found to be located in a predicted PPARγ/RXRα bind-
ing motif, and the nucleotide variant A-allele disrupted reporter
expression that was co-stimulated by PPARγ/RXRα and their
cognate ligands. Physiologically, the minor A-allele is associ-
ated with lower leptin secretion, as well as lower BMI, espe-
cially in women (39). SNP rs7610 (minor T-allele) has been
identified in CHGA, showed decreased reporter expression in
PC12 pheochromocytoma cells, and was associated with lower
plasma chromogranin A levels and blood pressure (BP) in a
sex-dependent manner (40). Other polymorphisms identified in
CHGA coding sequence (rs9658667, G- to A-allele, Gly364Ser,
and rs9658668, C- to T-allele, Pro370Leu) result in altered cat-
estatin activity, changing its potency to inhibit nicotinic acetyl-
choline receptor (nAChR)-stimulated catecholamine release from
chromaffin cells, and likely linking these SNPs to an increased
risk of developing hypertension (41, 42). SNP rs9658635 and
haplotype (C-T) of SNPs rs9658635–rs729940 are both linked
to the onset of schizophrenia in the Japanese population, but
their effect on CHGA gene expression remains to be deter-
mined (43).
Chromogranin B (CHGB)
Reduced chromogranin B levels have been observed in the thal-
amic subregion, the mediodorsal nucleus, parvocellular division
(MDNp; CHGB mRNA levels), and cerebrospinal fluid (both
CgA and CgB protein levels) of schizophrenic patients (44, 45).
Two polymorphisms identified in the CHGB coding sequence,
rs236152 (C- to G-allele, Arg353Gly) and rs236153 (A- to G-
allele, Glu368Glu), are associated with schizophrenia in a Japan-
ese population study, although the functional consequences of
these two SNP variants are unknown (46). A haplotype (A-T)
of SNPs rs236140–rs236141 identified in the CHGB gene pro-
moter region shows the highest transcriptional strength in reporter
assays carried out in PC12 cells, and interestingly, the (A-T) hap-
lotype is strongly associated with hypertension (47). The SNP
rs2821 (minor A-allele) found in an RNA-destabilizing A/U-rich
motif of the CHGB 3′UTR was reportedly associated with lower
plasma chromogranin B levels in population studies, likely due to
shortened CHGB mRNA half-life (48).
Secretogranin II and secretogranin III (SCG2 and SCG3)
Single nucleotide polymorphism rs1017448 (minor A-allele) was
found in the first intron of the SCG2 gene. It is significantly
associated with elevated BP, and likely increases SCG2 gene
expression by facilitating the recruitment of paired-like home-
obox transcriptional factor 2a (Phox2a) (49). SNP rs3764220
(A-allele), which is found in the promoter region of the SCG3
gene, is associated with metabolic syndrome-related physiologi-
cal changes, including dyslipidemia, hypertension, and impaired
glucose tolerance, with increased risk of cardiovascular disease-
related morbidity and mortality (50). SNP rs16964465 (minor
C-allele) in the SCG3 promoter region and minor G-allele of
rs16964476 in the first intron, both enhanced transcriptional
activity of a reporter in the neuroblastoma cell line SH-SY5Y
(51). Interestingly, in hypothalamus, SgIII protein is detected in
both POMC and NPY neurons in the arcuate nucleus, and in
orexin-expressing and melanin-concentrating hormone (MCH)-
expressing neurons in the lateral hypothalamus; all these neu-
ropeptides regulate food intake (51). Notably, these two minor
alleles, both associated with increased SgIII expression, seemed to
confer resistance to the onset of obesity, suggesting the possibility
that decreased SgIII levels could reciprocally increase the risk of
obesity.
PEPTIDASES AND CONVERTASES
Prohormone convertase 1/3
Prohormone convertases are a family of endopeptidases that cleave
proteins at internal sites, generally paired or clustered basic lysine,
and/or arginine residues. PC1 is encoded by the proprotein con-
vertase, subtilisin/kexin-type 1 (PCSK1) gene. Two functionally
relevant SNPs, originally identified in different PCSK1 alleles of a
female patient with childhood early onset obesity, are associated
with abnormal glucose homeostasis, and elevated plasma proin-
sulin and POMC levels (52, 53). SNP rs137852821 (G- to A-allele)
changes an amino acid from Gly483 to Arg483, which prevents
processing of proPC1 and favors its retention in the RER. Another
C-allele variant found in the intron-5 donor splice site of PCSK1
gene also causes exon 5 skipping and results in premature ter-
mination of PC1 translation in the catalytic region. Yet another
identified non-synonymous allele substitution that is associated
with early onset obesity is SNP rs6232 (A- to G-allele), which
changes Asn221 to Asp221 and causes impaired catalytic function
of PC1 (54).
Carboxypeptidase E
Carboxypeptidase E trims C-terminal lysine and arginine residues
from peptides that are generated by prohormone convertase
cleavage of precursor proteins at paired dibasic residues (55).
Notably, CPE is also a sorting/retention receptor for proinsulin
and proBDNF trafficking to the regulated secretory pathway (56,
57). The SNP rs144727363 (C- to T-allele, Arg189Trp) in the
CPE coding region changes arginine to tryptophan, which reduces
enzymatic activity of CPE, and is associated with hyperproinsu-
linemia and type II diabetes mellitus in affected Ashkenazi Jewish
families (58). Similarly, a missense mutation in the CPE gene
(Ser202Pro), identified from the mouse fat/fat model, which gen-
erates an enzymatically inactive and unprocessed protein product,
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results in impaired processing of proinsulin and other propeptides,
chronic hyperproinsulinaemia, and obesity (59–61).
OTHER PROTEINS THAT REGULATE SECRETORY PATHWAY FUNCTION
ATP6V0A1
ATP6V0A1 encodes the α1 subunit of the vacuolar H+-
translocating ATPase complex, which functions in acidification of
intracellular organelles. Bafilomycin A1,a chemical inhibitor of the
vacuolar H+ ATPase, impairs DCG formation, and the sorting of
secretory proteins into the regulated pathway (62). A reported SNP
rs938671 (minor C-allele, 3246 T/C) in the 3′UTR of ATP6V0A1
gene creates a binding motif for the micro-RNA hsa-miR-637,
which decreases overall gene expression of ATP6V0A1. Its clinical
association with hypertension may be due to altered DCG acidifi-
cation by the risk C-allele, and as a consequence, decreased sorting,
retention, and/or processing of DCG components (63).
Sortilin (SORT1)
Sortilin, a Vps10p domain protein, binds to proBDNF, and other
polypeptides and facilitates their trafficking into the regulated
secretory pathway (15). Plasma membrane sortilin also functions
as an internalization receptor for apolipoprotein A-V and pro-
granulin uptake (64, 65). Several SNPs are located in a non-coding
region downstream of the SORT1 allele and strongly correlate with
increased sortilin expression, including SNP rs12740374 (minor T-
allele), which creates a C/EBPα binding site, SNP rs646776 (minor
C-allele), and SNP rs599839 (minor G-allele). Increased sortilin
expression is reported to associate with reduced ApoB secretion,
enhanced LDL uptake in the liver, and increased uptake of plasma
progranulin (66–69). How these existing SNPs affect other known
function of sortilin, including propeptide sorting, is still unclear.
FUTURE PERSPECTIVES
Protein secretion from neuroendocrine, neural, and endocrine
cells is a complex, highly regulated process. Due to the nature
of the cargo, which includes critical growth factors, hormones,
peptide precursors, the enzymes that process them, and proteins
that function in secretory vesicle biogenesis, subtle alterations
in the regulated secretory pathway, and/or the proteins tran-
siting through it, can have a significant physiological impact.
Many studies reviewed here describe the association of specific,
discrete SNPs in the genes of secreted proteins with the risk
or onset of human disease. Neuropsychiatric disorders such as
schizophrenia, metabolic disorders including obesity and dia-
betes, and hypertension are strongly associated with a number
of well-characterized SNPs. These identified SNPs together with
genome-wide association studies (GWAS) and molecular and cel-
lular analyses of SNP function will advance our understanding of
the process of regulated secretion and the important roles that
secreted and secretory proteins play in maintaining physiological
homeostasis.
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